10-K: iSpecimen Reports Steep Revenue Decline, Ongoing Losses

iSpecimen Inc. disclosed a 79% revenue drop and continued net losses in its 2025 annual report, alongside significant cost reductions and ongoing legal challenges, raising substantial doubt about its ability to continue as a going concern.

Summary

• Reported a net loss of $10,487,532 for the year ended December 31, 2025, an improvement from $12,497,805 in 2024.
• Revenue decreased by 79% to $1,928,998 in 2025 from $9,291,115 in 2024, primarily due to a 77% decrease in specimen count (from 23,139 to 5,425).
• The average selling price per specimen decreased by 11% from approximately $402 in 2024 to $356 in 2025.
• Accumulated deficit reached $82,350,149 as of December 31, 2025.
• Cash and cash equivalents increased significantly to $6,880,835 in 2025 from $1,878,408 in 2024, largely due to equity financing.
• Working capital improved from a deficiency of $2,182,488 in 2024 to a positive $723,284 in 2025.
• Identified a material weakness in internal control over financial reporting related to sales tax documentation, calculation, collection, reporting, and remittance.
• The company is not in compliance with Nasdaq's minimum bid price requirement ($1.00) as of November 19, 2025, and has until May 18, 2026, to regain compliance.
• Significant cost reductions were implemented, including an estimated 67% reduction in monthly compensation costs and 25% in technology costs from January 1, 2024, through December 31, 2025, compared to 2024.
• The company faces several legal proceedings, including claims from Focus Technology Solutions, Inc. ($489,572), Azenta US, Inc. ($651,262), and Krisbio, LLC ($266,380). A claim from Ellenoff Grossman & Schole, LLP ($425,684) was settled for $200,000 post-year-end.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly concerning report. The drastic 79% revenue decline, coupled with persistent net losses and an explicit "going concern" warning, indicates severe operational and financial instability. The Nasdaq minimum bid price non-compliance adds significant delisting risk, further eroding investor confidence despite recent capital injections.

Positives

• Net loss decreased by 16% from $12,497,805 in 2024 to $10,487,532 in 2025.
• Cash and cash equivalents increased by 266% to $6,880,835 in 2025 from $1,878,408 in 2024.
• Working capital improved from a deficiency of $2,182,488 in 2024 to a positive $723,284 in 2025.
• Significant cost-cutting measures resulted in an estimated 67% reduction in monthly compensation costs and 25% in technology costs from January 1, 2024, through December 31, 2025, compared to 2024.
• Successfully raised capital through multiple equity financings in 2025, including an underwritten public offering ($3,999,574 gross), a private placement ($1,749,998 gross), and Series C convertible preferred stock ($5,500,000 gross).
• Implemented a "next day quote system" in Q3 2023, leading to a 44% increase in conversion ratios of quotes to purchase orders in 2024 and 2025.
• Percentage of specimens meeting specifications increased year-over-year, reaching 99% for clinical remnant and custom research collections, and 92% for banked research specimens in 2025.
• Modernized its technology platform by investing $1,000,000 in software under development in 2025 for a cloud-native, next-generation architecture.

Negatives

• Revenue decreased by 79% from $9,291,115 in 2024 to $1,928,998 in 2025.
• Specimen count decreased by approximately 77% from 23,139 in 2024 to 5,425 in 2025.
• Average selling price per specimen decreased by 11% from $402 in 2024 to $356 in 2025.
• The company has incurred losses since inception and anticipates continued losses, with an accumulated deficit of $82,350,149 as of December 31, 2025.
• There is "substantial doubt about our ability to continue as a going concern."
• Identified a material weakness in internal control over financial reporting related to sales tax obligations.
• Not in compliance with Nasdaq's minimum bid price requirement ($1.00) as of November 19, 2025, risking delisting.
• Other income (expense), net, shifted from a positive $230,240 in 2024 to a negative $1,509,613 in 2025.
• Workforce reduced from 24 employees in 2024 to 7 employees in 2025, indicating significant scaling back of operations.
• The company is supply-constrained, receiving more requests than it can fulfill.
• Reliance on relatively few customers for a significant portion of revenue (one customer accounted for 20% in 2025, 29% in 2024) and a non-recurring revenue business model.
• Customer retention rates are moderate, with only 48% of top 25 customers from 2024 procuring specimens in 2025.
• The iSpecimen Marketplace does not fully support self-service eCommerce, requiring assistance from sales personnel, which limits scalability.
• Incurred losses from sales tax obligations in prior years due to failure to collect taxes, and may not recover all prior sales taxes from customers.
• Wrote off $1,871,064 of internally developed software and $525,000 of other intangible assets in 2025.

Risks

• Incurred losses since inception and anticipates continued losses, may never achieve or sustain profitability.
• Substantial doubt about the ability to continue as a going concern.
• Material weakness in internal control over financial reporting related to sales tax obligations.
• Likely requires additional capital in the future, and inability to meet future capital needs could adversely impact operations.
• Revenue trend is not predictive, making accurate forecasting difficult due to transactional nature, customer concentration, and project-based needs.
• International operation expansion exposes the company to risks like political/economic changes, trade restrictions, currency fluctuations, and difficulty enforcing contracts.
• Reliance on technology solution; defects or failures could harm business and reputation.
• Sustainable future revenue growth depends on developing technology solutions that enable scale and address new markets, which requires significant investment.
• Security breaches or attacks could harm reputation, lead to loss of customers/suppliers, and incur significant legal/financial exposure.
• Challenges in establishing sales, marketing, and distribution capabilities globally could affect profitability.
• Reliance on few customers for significant revenue and a non-recurring revenue model.
• Customers may be averse to using a self-service marketplace, requiring personnel intervention and impacting scalability.
• Contracts with U.S. government agencies subject the company to federal contract and audit risks.
• Lengthy adoption cycle for supply network (up to 18 months for contract, several months to a year for implementation) may hinder rapid scaling.
• Changes in the healthcare industry (consolidations, regulatory changes) could affect access to subjects, samples, and data.
• Does not control end-to-end quality of specimens and data from supply chain, leading to potential quality issues.
• Reliance on relatively few supply partners for significant supplies and services.
• Specimen collection from human subjects carries risks of adverse events, leading to claims and litigation.
• May lose business to competitors with their own biorepositories or collection centers.
• Incurred losses from sales tax obligations in prior years and may not recover them from customers.
• May incur additional debt, subject to restrictive covenants.
• No patents protecting intellectual property; relies on trade secrets, which are difficult to protect.
• Failure to comply with federal, state, and international data protection regulations (HIPAA, GDPR) could result in fines, penalties, and litigation.
• Product safety and product liability, including bio-hazard risks, could lead to claims and litigation.
• No assurance of continued active and liquid trading market for common stock or compliance with Nasdaq listing standards.
• Not in compliance with Nasdaq's minimum bid price requirement, risking delisting.
• Sale of substantial shares of common stock may depress stock price.
• Need for additional capital may result in dilution to stockholders.
• Does not expect to pay dividends in the foreseeable future.
• Directors, officers, and principal stockholders have significant voting power.
• Bylaws designate certain courts as sole forum for certain actions, potentially limiting stockholder ability to obtain favorable judicial forum.
• Limitations on director and officer liability and indemnification may discourage suits against them.
• Quarterly revenue tends to fluctuate, making forecasting difficult.
• Stock price may be volatile.
• Status as an emerging growth company may make it harder to raise capital or make stock less attractive.
• Limited insurance may not cover all third-party claims.
• Requirements of being a U.S. public company strain resources and divert management attention.
• Evaluation of internal control and remediation of problems will be costly and time-consuming.
• Impact of the Russian-Ukrainian war on supply chain and operations.
• Supply partners' inventories may become obsolete.
• Credit risk with customers, especially privately held, investor-backed biopharma companies.
• Delays or interruptions in specimen shipments due to factors outside of control.
• Difficulty managing growth.
• Ability to utilize net operating loss carryforwards may be limited.
• May acquire other businesses, products, or technologies that could disrupt business or dilute stockholders.
• Use of third-party technology licenses and open-source licenses may subject to claims.
• May face pricing pressure from competitors.
• Overall business results may suffer from an economic downturn.
• Adverse impact from high inflation rates on employee salaries and operating costs.

Future Outlook

The company plans to continue investing in its iSpecimen Marketplace platform to enhance performance, functionality, ease of use, and reliability, focusing engineering resources on this development. It aims to expand platform capabilities to drive increased acquisition of annotated biospecimens, further grow its customer and supplier base globally, and explore new lines of business such as patient recruitment and data licensing. Strategic initiatives include enhancing customer experience, increasing supplier engagement, improving operational efficiency, and leveraging strategic business intelligence for market insights and sales funnel acceleration.

Management Comments

• "Our mission is to accelerate life science research, discovery and development with a global marketplace platform that connects researchers to subjects, specimens, and associated data."
• "Our vision is to create an Amazon-like global Marketplace of patients, biospecimens, and data for research to improve the quality of human life."
• "We believe with additional investment in technology development resources, we could make significant progress in scaling our iSpecimen Marketplace."
• "We believe that our business will continue to be resilient through a continued industry-wide economic slowdown in life science research, and that we will continue to work on improving our liquidity to address our financial obligations and alleviate possible adverse effects on our business, financial condition, results of operations or prospects."
• "Executive management of the Company continues to review the Companys structure, processes, and resources to evaluate and identify areas for improvement, and has been focused on creating and ensuring a runway for growth and scale for the business."
• "We are committed to developing our technology, we are investing at a significantly lower level in 2025 when compared to 2024 and prior years, while we focus on growing our revenues through key market opportunities and assessing our capital raise prospects."
• "We have shifted our focus from high volume to high value suppliers that meet our newly defined costs, quality and speed requirements."
• "Going forward, we will leverage the hard work detailed above to support a sales overhaul. This starts with a new account-based sales approach and the introduction of an outbound sales team to ensure we are meeting our customers and prospects where they are."

Industry Context

StockSavvy.ai notes that iSpecimen operates in a highly fragmented biospecimen procurement market, aiming to disrupt it with a technology-driven marketplace similar to travel websites. The company faces competition from traditional healthcare providers, commercial biobanks, specimen brokers, and research services marketplaces, many of whom are consolidating and are well-capitalized by private equity. The industry is driven by increasing demand for human biospecimens and clinical data due to advances in precision medicine and diagnostic/therapeutic product development. iSpecimen's strategy to leverage technology for scalability and efficiency positions it against competitors who rely more on manual efforts, though the slow adoption cycle for its supply network remains a challenge. The economic downturn impacting R&D budgets in biopharma also presents a headwind for the industry.

Comparison to Industry Standards

• iSpecimen aims to create an "Amazon-like global Marketplace," suggesting a goal to achieve market dominance and efficiency comparable to leading e-commerce platforms, which is a high benchmark.
• The company's technology-based approach is contrasted with competitors who rely on "manual efforts to procure specimens," implying a potential long-term efficiency advantage over traditional biobanks and brokers like Discovery Life Sciences and StemExpress (who maintain internal biobanks) or Science Exchange (which acts as a directory).
• The stated customer retention rate of 48% for top customers year-over-year is moderate, indicating a challenge in building recurring revenue compared to SaaS models prevalent in other tech-driven industries.
• The company's "just in time" procurement model is presented as an advantage over "traditional inventory-based supplier business model where biorepositories take inventory risks," suggesting a more capital-efficient approach compared to competitors who maintain large banked inventories.

Management Changes

Corporate Governance

Legal Proceedings

• **Focus Technology Solutions, Inc. v. iSpecimen**: Focus filed a complaint on December 9, 2024, alleging non-payment of approximately $489,572 for IT services. Focus disabled the company's platform from January 25, 2025, through February 12, 2025. A settlement agreement for $500,000 was reached on February 11, 2025, but Focus failed to fully restore the platform. The company withheld further payments and asserted counterclaims for consequential damages. A court order for pre-judgment security of $420,000 (15% of net revenue) was issued. Focus reduced its settlement demand to $100,000, which the company rejected after offering $30,000. The case is in the discovery phase.
• **Azenta US, Inc. v. iSpecimen, Inc.**: Azenta initiated a claim on or around January 15, 2025, for $651,262 alleging breach of contract and unjust enrichment related to sequencing services provided in 2023. The company believes it has valid defenses and has offered $125,000 to settle. Discovery has closed, and Azenta is expected to move for summary judgment.
• **Krisbio, LLC v. iSpecimen, Inc.**: The company was served with a Summons and Complaint on or about September 23, 2025, seeking $266,380 for alleged breach of contract and quasi-contractual claims related to a Participation Agreement. Initial disclosures have been filed, but formal discovery has not yet begun.
• **Ellenoff Grossman & Schole, LLP v. iSpecimen, Inc.**: EGS initiated a claim on or around November 14, 2024, for $425,684 for breach of contract and quantum meruit. This matter was settled subsequent to year-end on February 15, 2026, for $200,000.
• **Benjamin Bielak Arbitration**: Settled on January 30, 2025, for $215,000 regarding claims for bonus and severance payments.

Related Party Transactions

• No material related party transactions exceeding the lesser of $120,000 or 1% of total assets were reported for the fiscal years ended December 31, 2025 and 2024, nor are currently proposed.

Stakeholder Impact

• **Shareholders**: Significant dilution from multiple equity raises, potential for further dilution. Risk of delisting from Nasdaq could severely impact liquidity and market price. Ongoing losses and going concern doubt pose substantial risk to investment value.
• **Employees**: Significant workforce reduction (from 24 to 7 employees) indicates job insecurity and a leaner operational model. Inflation affecting employee salaries could impact morale and retention.
• **Customers**: Decreased specimen count and average selling price suggest reduced demand or ability to fulfill. Quality issues from the supply chain could affect customer satisfaction. The marketplace not being fully self-service may hinder customer experience.
• **Suppliers**: The "supplier network refresh project" involved terminating 180 agreements, impacting some suppliers. Reliance on few key suppliers creates risk. Delays in the procurement process could strain relationships.
• **Creditors**: Substantial doubt about going concern and ongoing losses increase credit risk. Legal proceedings and sales tax liabilities could impact the company's ability to meet its obligations.

Next Steps

• Continue to invest in the development of the iSpecimen Marketplace platform to enhance performance, functionality, ease of use, and reliability.
• Focus engineering resources on scaling the iSpecimen Marketplace and expanding into new lines of business (patient recruitment, data licensing, SaaS, Next Generation Sequencing).
• Enhance customer experience, increase supplier engagement, and improve operational efficiency.
• Implement a new account-based sales approach and introduce an outbound sales team.
• Bring marketing and sales closer to enable efficiencies within the commercial organization.
• Leverage strategic business intelligence to understand market needs and adjust supplier network and marketing efforts.
• Continue efforts to remediate the material weakness in internal control over financial reporting related to sales tax obligations.
• Monitor stock price and evaluate options to regain compliance with Nasdaq's minimum bid price requirement by May 18, 2026.
• Defend against ongoing legal proceedings from Focus Technology Solutions, Inc., Azenta US, Inc., and Krisbio, LLC.

Key Dates

Recommendation

iSpecimen Inc. faces severe financial distress, evidenced by a 79% revenue decline, persistent net losses, and an explicit "substantial doubt about our ability to continue as a going concern" warning. The company is also non-compliant with Nasdaq's minimum bid price, risking delisting. While recent capital raises provide temporary liquidity, they come with significant shareholder dilution. The drastic reduction in workforce and ongoing legal battles further highlight operational instability. The fundamental business model is struggling to generate sustainable revenue, making the stock a high-risk, low-reward investment.

Keywords

Biospecimen procurement, Life science research, Biopharma, Healthcare data, Marketplace platform, SEC filing, 10-K, Financial results, Going concern, Nasdaq delisting, Biorepositories, Clinical trials, Precision medicine, Biotechnology, Medical discovery, Sales tax liability, Internal controls, Capital raise, Legal proceedings, Corporate governance, Technology development, Supply chain, Risk management